Tweet
Emergent Biosolutions Inc (NYSE:EBS) Chairman Fuad El-Hibri sold 36,318 shares of the stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $55.98, for a total value of $2,033,081.64. The transaction was disclosed in a document filed with the SEC, which is available at this link .
Fuad El-Hibri also recently made the following trade(s): Get Emergent Biosolutions alerts: On Thursday, July 12th, Fuad El-Hibri sold 15,000 shares of Emergent Biosolutions stock. The stock was sold at an average price of $54.50, for a total value of $817,500.00. On Monday, July 9th, Fuad El-Hibri sold 15,000 shares of Emergent Biosolutions stock. The stock was sold at an average price of $53.61, for a total value of $804,150.00.
Shares of NYSE:EBS opened at $59.03 on Friday. Emergent Biosolutions Inc has a twelve month low of $34.56 and a twelve month high of $60.00. The firm has a market capitalization of $2.75 billion, a PE ratio of 30.87, a price-to-earnings-growth ratio of 1.18 and a beta of 1.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.59 and a quick ratio of 4.15.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $1.07 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.19. Emergent Biosolutions had a return on equity of 15.09% and a net margin of 16.55%. The company had revenue of $220.20 million during the quarter, compared to analyst estimates of $208.94 million. During the same period last year, the company posted $0.13 earnings per share. The firm's quarterly revenue was up 118.5% compared to the same quarter last year. equities analysts anticipate that Emergent Biosolutions Inc will post 2.33 earnings per share for the current year.
A number of brokerages have recently weighed in on EBS. Wells Fargo & Co set a $61.00 target price on Emergent Biosolutions and gave the company a "hold" rating in a research note on Friday, August 10th. Chardan Capital raised their target price on Emergent Biosolutions from $53.00 to $57.00 and gave the company a "buy" rating in a research note on Friday, August 3rd. Zacks Investment Research upgraded Emergent Biosolutions from a "hold" rating to a "buy" rating and set a $60.00 target price for the company in a research note on Tuesday, July 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Emergent Biosolutions in a research note on Thursday, June 14th. Finally, Argus began coverage on Emergent Biosolutions in a research note on Wednesday, June 13th. They issued a "buy" rating and a $62.00 target price for the company. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Emergent Biosolutions presently has a consensus rating of "Buy" and a consensus price target of $59.57.
Several large investors have recently made changes to their positions in EBS. Stratos Wealth Partners LTD. bought a new position in Emergent Biosolutions in the first quarter valued at about $134,000. PNC Financial Services Group Inc. boosted its holdings in Emergent Biosolutions by 108.6% in the first quarter. PNC Financial Services Group Inc. now owns 2,847 shares of the biopharmaceutical company's stock valued at $149,000 after acquiring an additional 1,482 shares during the last quarter. SG Americas Securities LLC bought a new position in Emergent Biosolutions in the first quarter valued at about $171,000. Financial Gravity Wealth Inc. bought a new position in Emergent Biosolutions in the first quarter valued at about $190,000. Finally, Sei Investments Co. boosted its holdings in Emergent Biosolutions by 5,992.1% in the first quarter. Sei Investments Co. now owns 3,838 shares of the biopharmaceutical company's stock valued at $202,000 after acquiring an additional 3,775 shares during the last quarter. Institutional investors own 82.72% of the company's stock.
About Emergent Biosolutions
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases